These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 30892083)

  • 1. Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer.
    O'Shaughnessy J; Kaklamani V; Kalinsky K
    Future Oncol; 2019 May; 15(14):1641-1653. PubMed ID: 30892083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eribulin mesylate (Halaven) for breast cancer.
    Med Lett Drugs Ther; 2011 Apr; 53(1362):30-1. PubMed ID: 21502935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eribulin mesylate for the treatment of late-stage breast cancer.
    Gourmelon C; Frenel JS; Campone M
    Expert Opin Pharmacother; 2011 Dec; 12(18):2883-90. PubMed ID: 22087618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
    Ates O; Babacan T; Kertmen N; Sarici F; Cenoli A; Akin S; Karakas Y; Kilickap S; Ozisik Y; Sever AR; Aksoy S; Altundag K
    J BUON; 2016; 21(2):375-81. PubMed ID: 27273947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eribulin: rediscovering tubulin as an anticancer target.
    Jimeno A
    Clin Cancer Res; 2009 Jun; 15(12):3903-5. PubMed ID: 19509144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment with eribulin in heavily pretreated women with metastatic breast cancer: a case series.
    Morritti M; Iodice G; Melaccio A; D'Onofrio L; Bergnolo P; Boglione A; Comandone A; Molinaro P; Garigliano D
    Future Oncol; 2017 Apr; 13(11s):25-33. PubMed ID: 28481183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma.
    Emambux S; Italiano A
    Expert Opin Pharmacother; 2017 Jun; 18(8):819-824. PubMed ID: 28468516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
    McIntyre K; O'Shaughnessy J; Schwartzberg L; Glück S; Berrak E; Song JX; Cox D; Vahdat LT
    Breast Cancer Res Treat; 2014 Jul; 146(2):321-8. PubMed ID: 24699910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review on the clinical use of eribulin mesylate for the treatment of breast cancer.
    Aseyev O; Ribeiro JM; Cardoso F
    Expert Opin Pharmacother; 2016; 17(4):589-600. PubMed ID: 26809667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.
    Park YH; Kim TY; Im YH; Lee KS; Park IH; Sohn J; Lee SH; Im SA; Kim JH; Kim SH; Lee SJ; Koh SJ; Lee KH; Choi YJ; Cho EK; Lee S; Kang SY; Seo JH; Kim SB; Jung KH
    Cancer Res Treat; 2017 Apr; 49(2):423-429. PubMed ID: 27488876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eribulin rapidly reduces the aggressiveness of second primary breast cancer: a case report.
    Falco I; Stragliotto S
    Future Oncol; 2017 Apr; 13(11s):51-54. PubMed ID: 28481187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-tumor mechanism and clinical efficacy of Eribulin (Halaven®), a new microtubulin inhibitor approved for treatment of metastatic breast cancer].
    Koyama N; Tokunaga T; Ogasawara W; Murakami M; Yamashita Y
    Nihon Yakurigaku Zasshi; 2011 Nov; 138(5):209-17. PubMed ID: 22075465
    [No Abstract]   [Full Text] [Related]  

  • 13. Eribulin as an effective monotherapy in a chemo-pretreated woman with metastatic breast cancer: a case report.
    Caputo R; Cianniello D; De Laurentiis M
    Future Oncol; 2017 Apr; 13(11s):45-50. PubMed ID: 28481184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eribulin efficacy based on type of metastatic site: a real-life study in heavily pretreated metastatic breast cancer.
    Prestifilippo A; Grippaldi D; Blanco G; Memeo L; Puliafito I; Giuffrida D
    Future Oncol; 2017 Apr; 13(11s):5-10. PubMed ID: 28481186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eribulin long-term response and rechallenge: report of two clinical cases.
    Barbieri E; Rubino D; Hakim R; Fini A; Lenzi M; Zamagni C
    Future Oncol; 2017 Apr; 13(11s):35-43. PubMed ID: 28481188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy.
    Pivot X; Marmé F; Koenigsberg R; Guo M; Berrak E; Wolfer A
    Ann Oncol; 2016 Aug; 27(8):1525-31. PubMed ID: 27177860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to eribulin in a difficult-to-treat, heavily pretreated breast cancer patient: a case report.
    Leo L; Caputo F; Sarno AD; Garofano T; Andreozzi F; Massaro MG; Montesarchio V
    Future Oncol; 2015; 11(15 Suppl):27-30. PubMed ID: 26235262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eribulin in advanced breast cancer: safety, efficacy and new perspectives.
    Garrone O; Miraglio E; Vandone AM; Vanella P; Lingua D; Merlano MC
    Future Oncol; 2017 Dec; 13(30):2759-2769. PubMed ID: 29219017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review.
    Polastro L; Aftimos PG; Awada A
    Expert Rev Anticancer Ther; 2014 Jun; 14(6):649-65. PubMed ID: 24852360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eribulin mesylate in advanced breast cancer: retrospective review of a single institute experience.
    Martella F; Bacci C; Giordano C; Montagnani F; Gelain E; Rabatti L; Fioretto L
    Future Oncol; 2015; 11(15 Suppl):31-6. PubMed ID: 26235263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.